LAKE FOREST, Calif. & WOODLAND PARK, N.J.--(BUSINESS WIRE)--Summit Health, part of Village MD and Genomic Testing Cooperative (GTC), the global leader in RNA innovation, are excited to announce today ...

VeloCD, a novel blood test, promises to forecast how illnesses will progress and the effectiveness of treatments. By ...

Scientists are developing a test which could one day be used to predict how a patient's illness will progress, and even how well they will respond to treatment. The international team, led by ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics first implemented RNA testing in 2016 as part of a research and ...

Cancer is most treatable in its early stages, so finding innovative and non-invasive methods to diagnose cancer early on is crucial for fighting the disease. Liquid biopsies, which require just a ...

Researchers at Imperial College London have developed VeloCD, a method using RNA blood markers to predict disease progression and treatment response within days. The technique, adapted from RNA ...

Ming, Professor of the Department of Chemical and Biological Engineering (CBE) at The Hong Kong University of Science and ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary ...

A lab is developing more accurate and powerful liquid biopsy technologies that take advantage of signals from RNA 'dark matter,' an understudied area of the genome. Cancer is most treatable in its ...

image: UC Santa Cruz Assistant Professor of Biomolecular Engineering Daniel Kim and his lab are developing more accurate and powerful liquid biopsy technologies that take advantage of signals from RNA ...